⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Lovastatin in Treating Patients At High Risk of Melanoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Lovastatin in Treating Patients At High Risk of Melanoma

Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology

Study ID: NCT00462280

Study Description

Brief Summary: The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma. This randomized phase II trial studies how well giving lovastatin or placebo works in treating patients at high risk of melanoma.

Detailed Description: PRIMARY OBJECTIVES: I. To evaluate the primary endpoint of the trial, by analysis of histopathologic regression of atypical nevi in response to a 6-month trial of oral (PO) lovastatin vs. placebo in subjects with atypical nevi. SECONDARY OBJECTIVES: I. To evaluate clinical regression of atypical nevi in the lovastatin vs. placebo group. II. To evaluate the secondary endpoint of changes in nevi numbers on subjects' backs in the lovastatin vs. placebo groups. III. To evaluate a number of molecular biomarkers as secondary endpoints in the lovastatin vs. placebo groups. IV. To evaluate the correlation of serum markers known to be affected by lovastatin with the endpoints chosen above. V. To evaluate the safety and tolerability of the dosing regimen, and the dose escalation. OUTLINE: Patients are randomized into 1 of 2 treatment arms per group. ARM I: Patients (with two matched nevi OR one large nevi) receive lovastatin PO once daily (QD) for up to 6 months in the absence of disease progression or unacceptable toxicity. ARM II: Patients (with two matched nevi OR one large nevi) receive placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 2 weeks.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of California Medical Center At Irvine-Orange Campus, Orange, California, United States

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Huntsman Cancer Institute, Salt Lake City, Utah, United States

Contact Details

Name: Kenneth Linden

Affiliation: Chao Family Comprehensive Cancer Center

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: